Soon to be revealed: latest EMA thinking on trial data disclosure
This article was originally published in SRA
Executive Summary
In just over two weeks' time we will have a better idea of how the European Medicines Agency plans to implement its decision on the proactive publication of clinical trial data on authorized drugs, when it releases the recommendations of the five advisory groups set up following last year's workshop on trial data and transparency1.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.